Pfizer and Eli Lilly will resume a late-stage study testing their pain drug tanezumab after the US Food and Drug Administration lifted a partial hold (...)

Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion-plus sa(...)

French pharmaceuticals group Sanofi has come under fire rom French government ministers over a   €4 million welcome bonus planned for its new CEO. Photo: Reuters

French pharmaceuticals group Sanofi came under fire from French government ministers on Monday over a welcome bonus planned for its new CEO.Sanofi’s n(...)

French drugmaker Sanofi has named Olivier Brandicourt, a Paris-educated doctor and head of Bayer’s healthcare arm, as its chief executive officer.

French drugmaker Sanofi has named Olivier Brandicourt, a Paris-educated doctor and head of Bayer’s healthcare arm, as its chief executive officer.Mr B(...)

Christopher Viehbacher, former Sanofi CEO. Photograph: Dylan Vaughan.

European pharmaceuticals group Sanofi on Thursday said it had agreed to pay €4.44 million in total to ousted chief executive Chris Viehbacher. Mr Vie(...)

Sanofi said the launch of new medicines and vaccines in other fields would help mitigate its dependence on Lantus, which accounts for nearly a fifth of sales

Sanofi, which sacked its chief executive three weeks ago, hopes to launch up to 18 new drugs by the end of 2020, with the potential to reap more than(...)

Christopher Viehbacher, ousted chief executive officer of French pharma group Sanofi. Photographer: Scott Eells/Bloomberg

Sanofi investors said former chief executive Chris Viehbacher, ousted today, paid the price for pushing too hard to make the French drugmaker more int(...)

Following on from Sunday’s stress test results, AIB was down by 5 per cent to 10 cents. Photograph:  Cyril Byrne

European shares rose yesterday, reversing the previous session’s dip as better-than-expected results from a number of blue-chips including pharma gro(...)

GlaxoSmithKline said last week it had received “very significant” indicative bids from private equity companies. Photographer: Chris Ratcliffe/Bloomberg

Private equity groups are exploring a $10 billion (€7.4 billion) plan to buy hundreds of older drug brands from GlaxoSmithKline (GSK) and Sanofi and m(...)

Property: its gains must be seen in the context of its recent fails

Who has the fairest fund of them all? If you’re looking for an investment with an element of risk, a fund is always an option for diversifying (...)